Tag: RASolute 302
-
Revolution Medicines Wins FDA Approval for Rasonque in Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma after Phase 3 RASolute 302 showed a major survival benefit over chemotherapy.